Nagaland News Today

DelveInsight Evaluates a Robust Anti-CD20 Antibody Clinical Trial Pipeline as 20+ Influential Pharma Companies to Set Foot in the 7MM

DelveInsight Evaluates a Robust Anti-CD20 Antibody Clinical Trial Pipeline as 20+ Influential Pharma Companies to Set Foot in the 7MM

September 08
09:15 2023
DelveInsight Evaluates a Robust Anti-CD20 Antibody Clinical Trial Pipeline as 20+ Influential Pharma Companies to Set Foot in the 7MM

The Anti-CD20 Antibody Pipeline Insight 2023 report by DelveInsight offers a thorough global overview of Anti-CD20 Antibody treatments, including those already in the market, as well as those in different phases of clinical development. Prominent pharmaceutical firms are dedicated to progressing the Anti-CD20 Antibody pipeline landscape and fostering the potential growth of Anti-CD20 Antibody therapeutic advancements.

 

Key Takeaways from the Anti-CD20 Antibody Pipeline Report

  • DelveInsight’s Anti-CD20 Antibody pipeline report depicts a robust space with 20+ active players working to develop 20+ pipeline therapies for Anti-CD20 Antibody treatment.
  • The leading companies working in the Anti-CD20 Antibody market include TG Therapeutics, Roche, Genmab/ Novartis, Biocad, Regeneron Pharmaceuticals, IGM Biosciences, Genentech, MENTRIK Biotech, Xencorm, KindredBio, Boehringer Ingelheim, Bioxpress therapeutics, 3SBio, Sinocelltech, Alopexx Oncology, Pfizer, Protheragen, Biogen Idec/Genentech, BioThera solutions, and others.
  • Promising Anti-CD20 Antibody Pipeline Therapies in the various stages of development include Zanubrutinib, Rituximab, Lenalidomide, Obinutuzumab, Ofatumumab, Cyclophosphamide, Doxorubicin, Acalabrutinib, Obinutuzumab and Pixantrone, and others.
  • On July 2023, University of Washington announced a study of Phase 2 Clinical Trials for Obinutuzumab, Rituximab, and Pembrolizumab. This phase II trial studies how well pembrolizumab with rituximab or obinutuzumab work in treating patients with follicular lymphoma or diffuse large B cell lymphoma that has come back (recurrent) or does not respond to treatment (refractory).
  • On July 2023, Cho Pharma Inc. announced a study of Phase 1 & 2 Clinical Trials for CHO-H01. This is a 2-part study. Part 1/Phase 1 of the study will be conducted to determine the safety and tolerability of CHO-H01 in subjects with relapsed/refractory CD20+ non-Hodgkin’s lymphoma. It will also determine maximum tolerated dose (MTD) and recommended phase II dose (RP2D).
  • On August 2023, BeiGene announced a study of Phase 3 Clinical Trials for Zanubrutinib, Rituximab, Lenalidomide, and Obinutuzumab. The purpose of the study is to compare the efficacy of zanubrutinib plus obinutuzumab versus lenalidomide plus rituximab (R^2) in participants with relapsed/refractory (R/R) follicular lymphoma (FL), as measured by progression-free survival as determined by an independent review committee in accordance with the 2014 modification of the International Working Group on non-Hodgkin lymphoma (NHL) Criteria based on n positron emission tomography and computed tomography (PET/CT), and to compare the efficacy of zanubrutinib plus rituximab versus R^2 in participants with R/R marginal zone lymphoma (MZL), as measured by progression free survival (PFS) assessed by IRC in accordance with CT-based Lugano 2014 Criteria.

 

Request a sample and discover the recent advances in Anti-CD20 Antibody Treatment Drugs @ Anti-CD20 Antibody Pipeline Report

 

The Anti-CD20 Antibody pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage Anti-CD20 Antibody drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the Anti-CD20 Antibody clinical trial landscape.

 

Anti-CD20 Antibody Overview

CD20 is a 33- to 37-kDa non-glycosylated phosphoprotein expressed on the surface of mature undifferentiated B-cells. Expression starts at the pre–B-cell stage, and persists until terminal differentiation into plasma cells.

 

Find out more about Anti-CD20 Antibody Treatment Drugs @ Drugs for Anti-CD20 Antibody Treatment

 

Anti-CD20 Antibody Emerging Drugs Profile

  • Ublituximab: TG therapeutics
  • Glofitamab: Roche

 

Anti-CD20 Antibody Pipeline Therapeutics Assessment

The Anti-CD20 Antibody pipeline report proffers an integral view of the Anti-CD20 Antibody emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration.

 

Learn more about the emerging Anti-CD20 Antibody Pipeline Therapies @ Anti-CD20 Antibody Clinical Trials Assessment

 

Scope of the Anti-CD20 Antibody Pipeline Report

  • Coverage- Global
  • Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
  • Anti-CD20 Antibody Companies- TG Therapeutics, Roche, Genmab/ Novartis, Biocad, Regeneron Pharmaceuticals, IGM Biosciences, Genentech, MENTRIK Biotech, Xencorm, KindredBio, Boehringer Ingelheim, Bioxpress therapeutics, 3SBio, Sinocelltech, Alopexx Oncology, Pfizer, Protheragen, Biogen Idec/Genentech, BioThera solutions, and others.
  • Anti-CD20 Antibody Pipeline Therapies- Zanubrutinib, Rituximab, Lenalidomide, Obinutuzumab, Ofatumumab, Cyclophosphamide, Doxorubicin, Acalabrutinib, Obinutuzumab and Pixantrone, and others.

 

Dive deep into rich insights for new drugs for Anti-CD20 Antibody Treatment, Visit @ Anti-CD20 Antibody Market Drivers and Barriers, and Future Perspective

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Anti-CD20 Antibody: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Anti-CD20 Antibody – DelveInsight’s Analytical Perspective
  7. In-depth Commercial Assessment
  8. Anti-CD20 Antibody Collaboration Deals
  9. Late Stage Products (Preregistration)
  10. Ublituximab: TG therapeutics
  11. Drug profiles in the detailed report…..
  12. Mid Stage Products (Phase II)
  13. Odronextamab: Regeneron Pharmaceuticals
  14. Drug profiles in the detailed report…..
  15. Early stage products (Phase I)
  16. IGM 2323: IGM Biosciences
  17. Drug profiles in the detailed report…..
  18. Inactive Products
  19. Anti-CD20 Antibody Key Companies
  20. Anti-CD20 Antibody Key Products
  21. Anti-CD20 Antibody- Unmet Needs
  22. Anti-CD20 Antibody- Market Drivers and Barriers
  23. Anti-CD20 Antibody- Future Perspectives and Conclusion
  24. Anti-CD20 Antibody Analyst Views
  25. Anti-CD20 Antibody Key Companies
  26. Appendix

  

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting